Literature DB >> 26673949

Using Akaike's information theoretic criterion in mixed-effects modeling of pharmacokinetic data: a simulation study.

Erik Olofsen1, Albert Dahan1.   

Abstract

Akaike's information theoretic criterion for model discrimination (AIC) is often stated to "overfit", i.e., it selects models with a higher dimension than the dimension of the model that generated the data. However, with experimental pharmacokinetic data it may not be possible to identify the correct model, because of the complexity of the processes governing drug disposition. Instead of trying to find the correct model, a more useful objective might be to minimize the prediction error of drug concentrations in subjects with unknown disposition characteristics. In that case, the AIC might be the selection criterion of choice. We performed Monte Carlo simulations using a model of pharmacokinetic data (a power function of time) with the property that fits with common multi-exponential models can never be perfect - thus resembling the situation with real data. Prespecified models were fitted to simulated data sets, and AIC and AIC c (the criterion with a correction for small sample sizes) values were calculated and averaged. The average predictive performances of the models, quantified using simulated validation sets, were compared to the means of the AICs. The data for fits and validation consisted of 11 concentration measurements each obtained in 5 individuals, with three degrees of interindividual variability in the pharmacokinetic volume of distribution. Mean AIC c corresponded very well, and better than mean AIC, with mean predictive performance. With increasing interindividual variability, there was a trend towards larger optimal models, but with respect to both lowest AIC c and best predictive performance. Furthermore, it was observed that the mean square prediction error itself became less suitable as a validation criterion, and that a predictive performance measure should incorporate interindividual variability. This simulation study showed that, at least in a relatively simple mixed effects modelling context with a set of prespecified models, minimal mean AIC c corresponded to best predictive performance even in the presence of relatively large interindividual variability.

Entities:  

Keywords:  population model, pharmacokinetics, Akaike, information theoretic criterion

Year:  2013        PMID: 26673949      PMCID: PMC4670010          DOI: 10.12688/f1000research.2-71.v2

Source DB:  PubMed          Journal:  F1000Res        ISSN: 2046-1402


  2 in total

Review 1.  Noncompartmental models of whole-body clearance of tracers: a review.

Authors:  K H Norwich
Journal:  Ann Biomed Eng       Date:  1997 May-Jun       Impact factor: 3.934

Review 2.  Use and abuse of variance models in regression.

Authors:  J C van Houwelingen
Journal:  Biometrics       Date:  1988-12       Impact factor: 2.571

  2 in total
  15 in total

1.  Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures.

Authors:  Sebastian Palmqvist; Pontus Tideman; Nicholas Cullen; Henrik Zetterberg; Kaj Blennow; Jeffery L Dage; Erik Stomrud; Shorena Janelidze; Niklas Mattsson-Carlgren; Oskar Hansson
Journal:  Nat Med       Date:  2021-05-24       Impact factor: 53.440

2.  Population pharmacokinetic modeling of plasma Δ9-tetrahydrocannabinol and an active and inactive metabolite following controlled smoked cannabis administration.

Authors:  Cristina Sempio; Marilyn A Huestis; Susan K Mikulich-Gilbertson; Jost Klawitter; Uwe Christians; Thomas K Henthorn
Journal:  Br J Clin Pharmacol       Date:  2020-01-20       Impact factor: 4.335

3.  A pharmacological rationale for improved everolimus dosing in oncology and transplant patients.

Authors:  R Ter Heine; N P van Erp; H J Guchelaar; J W de Fijter; M E J Reinders; C M van Herpen; D M Burger; D J A R Moes
Journal:  Br J Clin Pharmacol       Date:  2018-05-06       Impact factor: 4.335

4.  The effect of neutropenia on the clinical pharmacokinetics of vancomycin in adults.

Authors:  Didi Bury; Rob Ter Heine; Ewoudt M W van de Garde; Marten R Nijziel; Rene J Grouls; Maarten J Deenen
Journal:  Eur J Clin Pharmacol       Date:  2019-03-15       Impact factor: 2.953

5.  Application of quantitative protein mass spectrometric data in the early predictive analysis of target engagement by monoclonal antibodies.

Authors:  Morris Muliaditan; Armin Sepp
Journal:  Clin Transl Sci       Date:  2022-04-28       Impact factor: 4.438

6.  Prognostic value of routine laboratory variables in prediction of breast cancer recurrence.

Authors:  Zhu Zhu; Ling Li; Zhong Ye; Tong Fu; Ye Du; Aiping Shi; Di Wu; Ke Li; Yifan Zhu; Chun Wang; Zhimin Fan
Journal:  Sci Rep       Date:  2017-08-15       Impact factor: 4.379

7.  Pharmacokinetic Study of Biotransformation Products from an Anxiolytic Fraction of Tilia americana.

Authors:  Virgilio Alfonso Juárez Ramírez; María Isabel Jiménez-Beltrán; Alejandro Zamilpa; Maribel Herrera-Ruiz; Rodolfo Abarca-Vargas; Galia Lombardo-Earl; Jaime Tortoriello; Enrique Jiménez-Ferrer
Journal:  Molecules       Date:  2017-07-27       Impact factor: 4.411

8.  Plasma biomarkers of Alzheimer's disease improve prediction of cognitive decline in cognitively unimpaired elderly populations.

Authors:  Niklas Mattsson-Carlgren; Oskar Hansson; Nicholas C Cullen; Antoine Leuzy; Shorena Janelidze; Sebastian Palmqvist; Anna L Svenningsson; Erik Stomrud; Jeffrey L Dage
Journal:  Nat Commun       Date:  2021-06-11       Impact factor: 14.919

9.  Pharmacokinetic profile of enrofloxacin and its metabolite ciprofloxacin in Asian house geckos (Hemidactylus frenatus) after single-dose oral administration of enrofloxacin.

Authors:  Jessica E Agius; Benjamin Kimble; Merran Govendir; Karrie Rose; Charley-Lea Pollard; David N Phalen
Journal:  Vet Anim Sci       Date:  2020-05-05

10.  Accurate risk estimation of β-amyloid positivity to identify prodromal Alzheimer's disease: Cross-validation study of practical algorithms.

Authors:  Sebastian Palmqvist; Philip S Insel; Henrik Zetterberg; Kaj Blennow; Britta Brix; Erik Stomrud; Niklas Mattsson; Oskar Hansson
Journal:  Alzheimers Dement       Date:  2018-10-23       Impact factor: 21.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.